I am a healthcare professional in the UK
I am a patient or member of the public
1 minute
ESOT Congress 2025 Audio Review with Congress Chair Prof Colin Wilson & Congress Committee Member Dr Rommel Ravanan
Themes:
Sustainability
Organ Recipient Selection
Incompatible Donors
Pharmacists at ESOT
Real World Data
Brightcove Video
References
SOLSTICE study: Avery RK, et al. Clin Infect Dis. 2022;75(4):690–701
Canada Genome: Dobrer S, et al. Front Immunol. 2024;14:1302627
French Compassionate Use Of Maribavir: Abstract N°: BOS60_03_6 Title: Leveraging French Compassionate Program data to describe maribavir use in refractory cytomegalovirus infection. Presented at ESOT 2025 and based on AAC Maribavir - Resume rapport de synthese (in French) https://share.google/yWFf5EdTGQt2INYbC
RPG Abstract : Abstract N°: BOS_19_6 Title: Maribavir use in managing cytomegalovirus infection among UK kidney transplant recipients Bryant et al, Presented at ESOT 2025
You might be interested in
download
This concise guide to LIVTENCITY® (maribavir) is designed for clarity and ease of use. It summarises key insights from the Phase 3 SOLSTICE trial, including efficacy outcomes, safety data, and practical dosing guidance.
article
6 minutes
A summary of the safety profile of LIVTENCITY, including adverse event data and tolerability findings from clinical studies.
article
5 minutes
Key efficacy outcomes from clinical trials evaluating LIVTENCITY in patients with post-transplant CMV, including virologic response and treatment comparisons.
article
3 minutes
CMV is one of the most common infections experienced by transplant recipients
article
4 minutes
An overview of the pivotal Phase 3 SOLSTICE trial, outlining the study design, patient population, and methodology that underpin the clinical evidence for LIVTENCITY.
